15th week of 2013 patent applcation highlights part 36 |
Patent application number | Title | Published |
20130090224 | INORGANIC FIBROUS MOLDED REFRACTORY ARTICLE, METHOD FOR PRODUCING INORGANIC FIBROUS MOLDED REFRACTORY ARTICLE, AND INORGANIC FIBROUS UNSHAPED REFRACTORY COMPOSITION - An inorganic fibrous shaped refractory article having a high bio-solubility which is capable of exhibiting a desired heat resistance without containing expensive ceramic fibers, alumina powder and silica powder can be provided at a low production cost and with a low product price. | 2013-04-11 |
20130090225 | OPTICAL GLASS AND OPTICAL ELEMENT - Provided is an optical glass which can satisfy all of the following requirements: (1) it contains no environmentally undesirable components; (2) it can easily achieve a low glass transition point; (3) it has a high refractive index and high dispersion; (4) it can easily provide a glass having a superior visible light transmittance; and (5) it has superior resistance to devitrification during preparation of a preform. The optical glass has a refractive index nd of 2.0 or more, an Abbe's number vd of 20 or less, a glass transition point of 450° C. or below, and a glass composition, in % by mass, of 70 to 90% Bi | 2013-04-11 |
20130090226 | Lead-Free Low Melting Point Glass Composition - Disclosed is a lead-free, low melting point glass composition, which is characterized by being substantially free from a lead component and comprising 0-8 mass % of SiO | 2013-04-11 |
20130090227 | LEAD-FREE GLASS FOR SEMICONDUCTOR ENCAPSULATION - The technical task of the present invention is to provide a lead-free glass for semiconductor encapsulation, which is easy to automate an appearance inspection, and furthermore, has excellent refinability and encapsulatability of semiconductor devices. In the lead-free glass for semiconductor encapsulation according to the present invention, a temperature at which the viscosity of glass is 10 | 2013-04-11 |
20130090228 | COMPOSITE BODY AND METHOD OF MAKING - A composite article having a body including a first phase that includes a nitride material, a second phase that includes a carbide material, and a third phase having one of an amorphous phase material with a nitrogen content of at least about 1.6 wt % or an amorphous phase material comprising carbon. | 2013-04-11 |
20130090229 | BINDER FOR MONOLITHIC REFRACTORIES, MONOLITHIC REFRACTORY, AND CONSTRUCTION METHOD OF MONOLITHIC REFRACTORIES - This binder for monolithic refractories includes a solid solution obtained by dissolving Ca components in α-SrAl | 2013-04-11 |
20130090230 | REFRACTORY POWDER COMPRISING COATED MULLITE GRAINS - A powder is disclosed having a coarse fraction representing more than 60% and less than 85% of the powder, as a weight percentage on the basis of the oxides, and that is constituted of particles having a size greater than or equal to 50 μm, referred to as “coarse particles”, the powder comprising at least 5% of coated grains having a size greater than or equal to 50 μm, as a weight percentage on the basis of the oxides of the powder, and a fine fraction, forming the balance to 100% as a weight percentage on the basis of the oxides, constituted of particles having a size of less than 50 μm, referred to as “matrix particles”. The powder can be applied in combustion chambers in which the temperature may reach 1400° C. | 2013-04-11 |
20130090231 | Alumina-Based Ceramic Materials and Process for the Production Thereof - The present invention provides a process for producing a ceramic material, which comprises: (a) forming a green compact by compacting a powder comprising alumina and carbon, wherein the powder is substantially free of silicon carbide and wherein the amount of carbon present in the powder does not exceed 0.1% by weight of the powder; and (b) sintering the green compact under non-oxidising conditions to form a ceramic material comprising alumina and carbon, wherein the green compact is sintered at a temperature of less than 1550° C. Ceramic materials obtainable by said process are also provided. | 2013-04-11 |
20130090232 | ULTRAFINE FIBER-BASED COMPOSITES HAVING HIGH HYDROSCOPICITY - The present invention relates to ultrafine fiber-based composites comprising at least one ultrafine fiber-type hydrophobic polymer and oxide moisture absorbent particles distributed on the polymer. The ultrafine fiber-based composites may be appropriately used as sealing materials which can prevent the functional deterioration of electric or electronic devices and enhance the stability due to their high hydroscopicity and ability to maintain their appearance without change after the absorption of moisture. | 2013-04-11 |
20130090233 | HYDROCRACKING PROCESS USING A ZEOLITE MODIFIED BY BASIC TREATMENT - The present invention describes a hydrocracking and/or hydrotreatment process using a catalyst comprising an active phase containing at least one hydrogenating/dehydrogenating component selected from the group VIB elements and the non-precious elements of group VIII of the periodic table, used alone or in a mixture, and a support comprising at least one dealuminated zeolite Y having an overall initial atomic ratio of silicon to aluminium between 2.5 and 20, an initial weight fraction of extra-lattice aluminium atoms greater than 10%, relative to the total weight of aluminium present in the zeolite, an initial mesopore volume measured by nitrogen porosimetry greater than 0.07 ml·g | 2013-04-11 |
20130090234 | Organotemplate-Free Synthetic Process For The Production Of A Zeolitic Material Of The LEV-Type Structure - Described is an organotemplate-free synthetic process for the production of a zeolitic material having an LEV-type framework structure comprising YO | 2013-04-11 |
20130090235 | ADDITIVES COMPRISING CELLULOSE ETHERS FOR CERAMICS EXTRUSION - The present invention relates to extrudable ceramic masses and other masses which set as a result of baking or sintering, which masses comprise specific additives based on water-soluble cellulose ethers, an extrusion process, the extrudates and their use. | 2013-04-11 |
20130090236 | CHITOOLIGOSACCHARIDES AND METHODS FOR USE IN ENHANCING SOYBEAN GROWTH - Disclosed are methods of enhancing growth of soybean plants, comprising treating soybean seed or the soybean plant that germinates from the seed with an effective amount of at least one chitooligosaccharide, wherein upon harvesting the soybean plant exhibits at least one of increased plant yield measured in terms of bushels/acre, increased root number, increased root length, increased root mass, increased root volume and increased leaf area, compared to untreated soybean plants or soybean plants harvested from untreated soybean seed. | 2013-04-11 |
20130090237 | PTEREDIN PENTANEDIOIC DERIVATIVE BASED NANOPARTICLES - In one embodiment, a method includes making a pteredin phenyl pentanedioic (3P) formulation by providing an aqueous solution including one of more 3P molecules neutralized with one or more of an alkali, an alkali earth metal hydroxide, or an alkali carbonate; adding to the aqueous solution one of a surfactant, dispersant, or additive with the guest molecules; and non-covalently crosslinking the 3P formulation by exposing the 3P formulation to an excess solution of multivalent cation salt. | 2013-04-11 |
20130090238 | Synergistic Fungicidal Composition And Methods Of Use - Described is a broad spectrum, synergistic fungicidal composition when used for the preservation of a glued wood product comprising as active ingredients: | 2013-04-11 |
20130090239 | STABLE, CONCENTRATED HERBICIDAL COMPOSITIONS - A liquid herbicidal composition is provided, comprising:
| 2013-04-11 |
20130090240 | EFFICACY-ENHANCING AGENT COMPOSITION FOR AGRICULTURAL CHEMICALS - The present invention provides the efficacy-enhancing agent composition for agricultural chemicals containing (A) the sorbitan fatty acid ester surfactant, (B) the rosin-oxyalkylene adduct surfactant or a specified quaternary ammonium salt surfactant, and (C) a specified glycol ether solvent. | 2013-04-11 |
20130090241 | SUPERCONDUCTIVE ELECTROMAGNET APPARATUS - A superconductive electromagnet apparatus and a magnetic resonance imaging apparatus including the superconductive electromagnet apparatus are provided. The superconductive electromagnet apparatus includes a thermal anchor, a cryogenic cooling device which cools the thermal anchor, and at least one connecting ring into which the thermal anchor is inserted and a plurality of wires which are connected to the connecting ring. | 2013-04-11 |
20130090242 | Techniques for Sub-Cooling in a Superconducting System - Techniques for sub-cooling in a superconducting (SC) system is disclosed. The techniques may be realized as a method and superconducting (SC) system comprising at least one insulated enclosure configured to enclose at least a first fluid or gas and a second fluid or gas, and at least one superconducting circuit within the at least one insulated enclosure. The superconducting (SC) system may be sub-cooled using at least the first fluid or gas. | 2013-04-11 |
20130090243 | SUPERCONDUCTING FAULT CURRENT LIMITER - This invention relates to a superconducting fault current limiter, including: an input segment of an input transformer core and an output segment of an output transformer, each segment having a first end and a second end; a length of superconductor which forms a winding around the input segment and a winding around output segment, wherein the windings are connected in series to form a closed loop; a cryostat in which the superconductor is housed; wherein each end of the input and output segments are exposed to the exterior of the cryostat. | 2013-04-11 |
20130090244 | SUPERCONDUCTING COIL, ROTATING DEVICE, AND SUPERCONDUCTING COIL MANUFACTURING METHOD - A superconducting coil and a rotating device, the performances of which are improved, and a superconducting coil manufacturing method are provided. A superconducting coil | 2013-04-11 |
20130090245 | METHOD FOR COOLING SUPERCONDUCTING JOINTS - A superconducting joint that electrically joins superconducting wires has a block of thermally and electrically conductive material that is coated with an electrically isolated coating that covers at least a part of a surface of the block. Molded semiconducting joint material is provided in contact with the electrically isolating coating. Superconducting filaments of the superconducting wires are embedded within the molded superconducting joint material. | 2013-04-11 |
20130090246 | METHOD OF GENERATING GENE MOSAICS - The invention relates to a method for generating a gene mosaic by somatic in vivo recombination, comprising: e) in a single step procedure (vii) transforming a cell with at least one gene A having a sequence homology of less than 99.5% to another gene to be recombined that is an integral part of the cell genome or presented in the framework of a genetic construct, (viii) recombining said genes, (ix) generating a gene mosaic of the genes at an integration site of a target genome, wherein said at least one gene A has a single flanking target sequence either at the 5′ end or 3′ end anchoring to the 5′ or 3′ end of said integration site, and f) selecting clones comprising the gene mosaic, as well as a method of producing a diversity of gene mosaics and gene assembly. | 2013-04-11 |
20130090247 | METHODS AND SYSTEMS FOR IDENTIFICATION OF BINDING PHARMACOPHORES - The invention provides systems and methods for generating 3D binding consensus pharmacophores. Initially, peptide screening sequence data is aligned. For one or more positions of the alignment: an observed distance matrix describing a distance between the relative binding activity of pairwise comparisons of each amino acid at the selected position is constructed, the observed distance matrix is compared to a plurality of field-based amino acid substitution matrices having the same shape as the observed distance matrix, preferred amino acid substitution matrices are identified from the plurality of amino acid substitution matrices based on the comparison, and a plurality of characteristics for the selected position are identified using the preferred amino acid substitution matrices. Characteristics for a plurality of positions of the alignment are used to generate three-dimensional peptide structures that represent predicted binding conformations. Molecular field information for these structures is clustered to determine a consensus field pharmacophore. | 2013-04-11 |
20130090248 | SELECTION OF COMPARTMENTALISED SCREENING - The present invention provides novel microfluidic substrates and methods that are useful for performing biological, chemical and diagnostic assays. The substrates can include a plurality of electrically addressable, channel bearing fluidic modules integrally arranged such that a continuous channel is provided for flow of immiscible fluids. | 2013-04-11 |
20130090249 | TOOLS FOR THE IDENTIFICATION OF LINGO-1, LINGO-2, LINGO-3 AND LINGO-4 LIGANDS, AND USES THEREOF - The present invention relates to a system comprising coupling products formed by a monomer of a protein chosen from Lingo-1, Lingo-2, Lingo-3 and Lingo-4 and by a probe emitting a signal when said monomer undergoes conformational changes, and to a screening method using said system, enabling ligands of a protein chosen from Lingo-1, Lingo-2, Lingo-3 and Lingo-4 to be identified. The present invention is industrially applicable in the field of methods for detecting molecules, for detecting interaction between molecules and for molecular screening, and also in the medical field. | 2013-04-11 |
20130090250 | ASSAY SYSTEMS FOR GENETIC ANALYSIS - The present invention provides assays systems and methods for detection of chromosomal abnormalities and status of single loci associated with monogenic or polygenic traits in a sample containing nucleic acids from a maternal and a fetal source. | 2013-04-11 |
20130090251 | Tumour Markers - A method of determining the immune response of a mammal to circulating tumour marker proteins is described in which a sample of bodily fluid, for example plasma or serum, is contacted with a panel of two or more distinct tumour marker antigen. The presence of complexes between the tumour marker antigens and any autoantibodies to the antigens present in the sample are detected and provide an indication of an immune response to a circulating tumour marker protein. The method is useful for the diagnosis of cancer, particularly for identifying new or recurrent cancer in an otherwise assymptomatic patient. | 2013-04-11 |
20130090252 | Quantitative, Highly Multiplexed Detection of Nucleic Acids - This invention provides methods of detecting and quantifying target nucleic acids in samples in multiplexed single chamber reactions. Consumables incorporating chambers optimized to reduce signal background proximal to high efficiency arrays are provided, as well as methods of use. Devices and systems configured to use the consumables to practice the methods are a feature of the invention. | 2013-04-11 |
20130090253 | ACCURATE QUANTITATION OF BIOMARKERS IN SAMPLES - Methods and apparatus for the accurate quantitation of biomarkers in dried blood spots (DBS), including providing a substrate comprising at least one DBS, wherein the DBS comprises at least one biomolecule distributed on the substrate in a gradient pattern; excising at least one sector-shaped sample from the DBS; and assaying the biomolecule in the sector-shaped sample. | 2013-04-11 |
20130090254 | GENE-EXPRESSION PROFILING WITH REDUCED NUMBERS OF TRANSCRIPT MEASUREMENTS - The present invention provides compositions and methods for making and using a transcriptome-wide gene-expression profiling platform that measures the expression levels of only a select subset of the total number of transcripts. Because gene expression is believed to be highly correlated, direct measurement of a small number (for example, 1,000) of appropriately-selected transcripts allows the expression levels of the remainder to be inferred. The present invention, therefore, has the potential to reduce the cost and increase the throughput of full-transcriptome gene-expression profiling relative to the well-known conventional approaches that require all transcripts to be measured. | 2013-04-11 |
20130090255 | Biological Markers of Chronic Wound Tissue and Methods of Using for Criteria in Surgical Debridement - The present invention relates to methods for identifying tissue sites in a chronic wound that are suitable for debridement and whether debridement procedure has been successful using particular biological markers of the cells within the tissue sites of the chronic wounds. | 2013-04-11 |
20130090256 | BIOMARKERS FOR EARLY DETECTION OF OVARIAN CANCER - Biomarker proteins that can be used in the diagnosis of early-stage ovarian cancer (OC) are described. The biomarker panels not only permit the distinction of patients with ovarian neoplasia (benign or malignant) from normal subjects, but they also allow the identification of patients with early-stage (stage I/II) ovarian cancer from those patients with benign ovarian tumors or normal individuals. The invention additionally provides methods for detecting and treating various cancers, including cancer of the ovary using OC-related molecules. | 2013-04-11 |
20130090257 | PATHWAY ANALYSIS FOR PROVIDING PREDICTIVE INFORMATION - A method for assigning ranking scores to pathways in a set of pathways for classifying patients is disclosed. The method comprises the steps of comparing biomolecular datasets from different groups of patients and performing an analysis in order to assign ranking scores to pathways in a set of pathways. Furthermore, a method for using cancer pathway evaluation to support clinical decision making is disclosed. This assessment is further used for stratifying ovarian cancer patients based on chemosensitivity to platinum based drugs, the standard chemotherapy. We present the method for evaluation and ranking of the most relevant pathways responsible for platinum sensitivity. Clinical decision support software system should be able to then visualize this information for a clinician, contextualize it within a patient data set and help make a final decision on the potential responsiveness. | 2013-04-11 |
20130090258 | METHOD FOR DETECTING COLORECTAL TUMOR - An object of the present invention is to provide a method for detecting a colorectal tumor, and particularly advanced adenoma and early cancer, by using a component contained in stool as an indicator. | 2013-04-11 |
20130090259 | IMPROVED METHOD FOR SELECTING HIGH PRODUCING CELL LINES - The invention provides methods for the rapid identification and selection of cell lines suitable for biopharmaceuticals production, which do no utilize animal derived components. | 2013-04-11 |
20130090260 | Multiplexed Assay Using Spectrally-Encoded Solid Support Matrices - In a multiplexed assay, each molecule of a plurality of molecules is attached to a support matrix particle with a substrate adapted for attachment and/or synthesis of molecules. A spectrally-encoded identifier embodied in a photochemical medium is embedded or encased within the substrate to uniquely identify the molecule attached to the substrate. The molecules are exposed to one or more processing conditions, and then placed within the path of an optical detector adapted to read the spectrally-encoded identifier and measure biochemical activity on each support matrix particle. The measured biochemical activity is associated with the unique identity of the support matrix particle and, hence, with the molecule attached to the particle. | 2013-04-11 |
20130090261 | Device for Determining or Studying the State of Stimulation of the Natural Defences of Plants or Portions of Plants - The present invention relates to a device for determining or studying the state of stimulation of the natural defenses of plants or plant portions, which plants advantageously belong to the Rosaceae family. The corresponding device includes means for determining the expression level, in a sample of plants or plant portions, of at least one target gene in each of the following groups (a) to (i): | 2013-04-11 |
20130090262 | SELECTIVE ENRICHMENT OF CpG ISLANDS - The present invention provides compositions and methods for selectively enriching genomic CpG island (CGI)- and other epigenetically informative CG-rich polynucleotide targets. The method involves co-incubation of denatured or partially denatured polynucleotide fragments containing the CGI- or CG-targeted region(s) of interest with an oligonucleotide capture pool collectively designed to selectively target CGIs. The oligonucleotide capture pool includes a plurality of different oligonucleotides, each oligonucleotide coupled to a capture tag, whereby the oligonucleotide includes a CpG target sequence restricted to 4 to 10 bases. Upon binding, capture oligonucleotides bound to the target fragments are enriched by separating the bound fragments from the unbound fragments. The enriched fragments may be subjected to further analyses, including bisulfite sequencing to generate a methylation profile at the single nucleotide level. | 2013-04-11 |
20130090263 | FLUORESCENT PROTEINS, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM - The invention is directed to polypeptides having a fluorescent activity, e.g., an auto-fluorescent activity, polynucleotides encoding the polypeptides, and methods for making and using these polynucleotides and polypeptides. The polypeptides of the invention can be used as noninvasive fluorescent markers in living cells and intact organs and animals. The polypeptides of the invention can be used as, e.g., in vivo markers/tracers of gene expression and protein localization, activity indicators, fluorescent resonance energy transfer (FRET) markers, cell lineage markers/tracers, reporters of gene expression and as markers/tracers in protein-protein interactions. | 2013-04-11 |
20130090264 | METAL NANOPARTICLE ARRAY STRUCTURE, DEVICE FOR PRODUCING SAME, AND METHOD FOR PRODUCING SAME - An object of the invention is to provide a metal nanoparticle array structure in which metal nanoparticle arrays are firmly bonded to the substrate thereof via chemical bonding or the like and in which the coverage with the metal nanoparticle arrays is high. | 2013-04-11 |
20130090265 | SYSTEMS AND METHODS FOR GENERATION OF CONTEXT-SPECIFIC, MOLECULAR FIELD-BASED AMINO ACID SUBSTITUTION MATRICES - Provided are systems and methods for generating context-specific, field based amino acid substitution matrices. In some implementations, the systems and methods utilize a set of characteristics including sequence length, sequence, variable position, backbone conformation, sidechain conformation, and charge and/or ionization state to construct a number of instantiated virtual peptide variants that vary an amino acid at the variable position. Molecular fields are then calculated for each instantiated variant. The fields for each variant are then compared to one another in a pairwise fashion. Values representing the similarity of the fields resulting from the comparison are then assembled into an amino acid substitution matrix. | 2013-04-11 |
20130090266 | METHODS AND SYSTEMS FOR OPTIMIZATION OF PEPTIDE SCREENING - The invention provides systems and methods for improved peptide screening library design. In some implementations the systems and methods utilize screening data relating to a plurality of peptides used in a peptide screen against a target molecule to construct a consensus binding sequence alignment using least a subset of the plurality of peptides. For one or more positions of the sequence alignment an observed distance matrix is constructed, the matrix describing a distance between the relative binding activity of pairwise comparisons of each amino acid in a given position. The observed distance matrix is then compared to a plurality of molecular field-based amino acid substitution matrices so as to identify one or more preferred amino acids for use in the design of novel predicted binding peptide sequences for a subsequent peptide screen. | 2013-04-11 |
20130090267 | TEMPERATURE CONTROL DEVICE WITH A FLEXIBLE TEMPERATURE CONTROL SURFACE - A device for controlling temperature in a reaction chamber is disclosed. The device comprises: a bladder assembly comprising a housing dimensioned to hold a reaction chamber disposed within an interior volume of the housing; and a first temperature-control bladder disposed within the housing, the first temperature-control bladder is configured to receive a temperature-control fluid and comprises a flexible, heat conductive surface that comes in contact with at least a portion of an exterior surface of the reaction chamber after receiving the temperature-control fluid. Also disclosed are a bladder thermal cycler, a temperature-control bladder assembly and methods for producing a thermal cycle in a reaction chamber. | 2013-04-11 |
20130090268 | VALVED, MICROWELL CELL-CULTURE DEVICE AND METHOD - A valved microfluidics device, microfluidics cell-culture device and system incorporating the devices are disclosed. The valved microfluidics device includes a substrate, a microchannel through which liquid can be moved from one station to another within the device, and a pneumatic microvalve adapted to be switched between open and closed states to control the flow of fluid through a microchannel. The microvalve is formed of three flexible membranes, one of which is responsive to pneumatic pressure applied to the valve and the other two of which deform to produce a more sealable channel cross-section. The cell culture device provides valving to allow controlled loading of cells into the individual well of the device, and exchange of cell-culture components in the wells. | 2013-04-11 |
20130090269 | DENDRITIC COMB-SHAPED POLYMER THICKENING AGENT, PREPARATON OF THE SAME AND APPLICATION THEREOF - The present invention relates to a dendritic comb-shaped polymer thickening agent and preparation and application thereof; it is a copolymer obtained by copolymerization of monomer (A) and monomer (B). Monomer (A) is one or more water-soluble unsaturated monomers with olefin chain, and monomer (B) is at least one monomer with the following general structure: | 2013-04-11 |
20130090270 | Method to Complex Metals in Aqueous Treating Fluids for Ves-Gelled Fluids - Aqueous treating fluids may include a viscoelastic surfactant (VES) and an aqueous base fluid, e.g. a drilling fluid, whereby the VES may increase and/or maintain the viscosity of the aqueous treating fluid. Metal ions may be present within the aqueous treating fluid that break, reduce, and/or digest the VES within the aqueous treating fluid. An effective amount of complexation particles may be added to the aqueous treating fluid for complexing at least a portion of these metal ions and thereby disallowing the metal ions from breaking, reducing, and/or altering the VES within the aqueous treating fluid. | 2013-04-11 |
20130090271 | INHIBITING CORROSION CAUSED BY AQUEOUS ALDEHYDE SOLUTIONS - Aldehydes useful as H | 2013-04-11 |
20130090272 | 170 NEUTRAL BASE OIL WITH IMPROVED PROPERTIES - We provide a base stock comprising hydrocarbons with consecutive numbers of carbon atoms, wherein the base stock has a boiling range from 388 to 538° C., a VI from 105 to less than 130, and a Noack volatility from 5 to 11.5 wt % or a CCS VIS at −25° C. from 2000 to 4000 mPa·s. We also provide a base stock slate comprising the base stock and an additional base stock having an additional boiling range from 371 to 496° C. and other properties. | 2013-04-11 |
20130090273 | LOW VISCOSITY ENGINE OIL COMPOSITIONS - This invention is directed to ultra-low viscosity passenger car engine oil compositions with a kinematic viscosity at 100° C. of from 4 to 6 cSt, and comprising in admixture 60 wt % to 90 wt % of a first base oil component, based on the total weight of the composition, the first base oil component consisting of a polyalphaolefin base stock or combination of polyalphaolefin base stocks, each having a kinematic viscosity at 100° C. of from 3.2 cSt to 3.8 cSt; and 0.1 wt % to 20 wt % of a second base oil component, based on the total weight of the composition, the second base oil component consisting of a Group II, Group III or Group V base stock, or any combination thereof; wherein the composition comprises from 0 wt % to less than 0.25 wt % viscosity index improver, on a solid polymer basis. | 2013-04-11 |
20130090274 | Low Viscosity Functional Fluids - (EN): Low viscosity functional fluids are described which comprises methoxy polyethylene glycol. The fluids are particularly well-suited for use as DOT 4 brake fluids and provide high ERBP, WERBP, low kinematic viscosity and low SBR volume % increase. | 2013-04-11 |
20130090275 | LUBRICATING OIL COMPOSITION FOR FLUID DYNAMIC BEARINGS AND HDD MOTOR FABRICATED USING THE SAME - There are provided a lubricating oil composition for a fluid dynamic bearing and and a hard disk drive (HDD) motor fabricated by using the same. The lubricating oil composition for a fluid dynamic bearing includes: an aliphatic mono carboxylic acid ester, as a base oil, obtained by esterification between carboxylic acid represented by the following Chemical Formula 1; and isopropyl alcohol: | 2013-04-11 |
20130090276 | LUBRICATING OIL COMPOSITION FOR FLUID DYNAMIC BEARING AND HDD MOTOR FABRICATED USING THE SAME - There are provided a lubricating oil composition for a fluid dynamic bearing and a hard disk drive (HDD) motor fabricated using the same. The lubricating oil composition for a fluid dynamic bearing includes: an aliphatic mono carboxylic acid ester, as a base oil, obtained by esterification between alcohol represented by the following Chemical Formula 1; and 2-ethylbutanoic acid: | 2013-04-11 |
20130090277 | LUBRICATING COMPOSITIONS - This invention is directed to lubricating compositions comprising a first base oil component consisting of a polyalphaolefin base stock or combination of polyalphaolefin base stocks, each having a kinematic viscosity at 100° C. of from 3.2 cSt to 3.8 cSt and obtained by a process comprising: (a) contacting a catalyst, an activator, and a monomer in a first reactor to obtain a first reactor effluent, the effluent comprising a dimer product, a trimer product, and optionally a higher oligomer product, (b) feeding at least a portion of the dimer product to a second reactor, (c) contacting said dimer product with a second catalyst, a second activator, and optionally a second monomer in the second reactor, (d) obtaining a second reactor effluent, the effluent comprising at least a trimer product, and (e) hydrogenating at least the trimer product of the second reactor effluent. | 2013-04-11 |
20130090278 | HIGH EFFICIENCY ENGINE OIL COMPOSITIONS - This invention is directed to passenger car engine oil compositions comprising in admixture | 2013-04-11 |
20130090279 | Shampoo Composition Containing a Gel Network - A shampoo composition having from about 5% to about 50% of a combination of sodium lauryl sulfate and sodium laureth-n sulfate, less than 3.82% of sodium laureth-n sulfate having n>1. The shampoo composition further includes from about 0.5% to about 3% of a co-surfactant selected from the group consisting of amphoteric, zwitterionic, and nonionic surfactants. The shampoo composition has a dispersed gel network phase having at least 0.05% of one or more fatty alcohols, at least 0.01% of one or more secondary surfactants, and water. The shampoo composition further includes at least about 20% of an aqueous carrier. The shampoo composition further has an enthalpy of transition from about 0 J/g to about 0.2 J/g as measured according to differential scanning calorimetry in a peak melt transition temperature range between about 18° C. to about 30° C. | 2013-04-11 |
20130090280 | CLEANING COMPOSITIONS AND METHODS - The present invention relates, in part, to compositions including at least one hydrofluoro-olefin or hydrochlorofluoro-olefin solvent. Such compositions may optionally contain one or more alcohols or other co-solvent or agent and may be used to provide one or more cleaning applications. | 2013-04-11 |
20130090281 | Phosphate And Phosphonate-Free Automatic Gel Dishwashing Detergent Providing Improved Spotting and Filming Performance - A phosphate and phosphonate-free gel automatic dishwashing detergent provides improved spotting and filming performance by including a spot reduction system that contains a combination of a polyacrylate and a carboxymethyl inulin. The gel detergent may also be free of a bleach ingredient (i.e., it does not contain either chlorine bleach or an oxygen bleach). | 2013-04-11 |
20130090282 | Thickener Containing A Cationic Polymer And Softening Composition Containing Said Thickener, In Particular For Textiles - A softening composition includes at least one thickener containing a cationic polymer obtained by polymerization:
| 2013-04-11 |
20130090283 | Aerosol Compositions - An aerosol composition with compressed gas propellant that is free of hydrocarbon propellants is described, wherein the composition comprises: 85.0 wt % to 98.0 wt % water; 0.01 wt % to 10.00 wt % low MW alcohol; 0.001 wt to 5.00 wt % surfactant; 0.001 wt to 5.00 wt % fragrance; 0.001 wt to 5.00 wt % borate salt; 0.001 wt to 5.00 wt % preservative. | 2013-04-11 |
20130090284 | ISOLATION, IDENTIFICATION, AND USES OF ANTIFUNGAL COMPOUNDS - In one aspect, the invention relates to isolated compounds useful as antifungal agents, for example, compounds having a structure represented by a formula: | 2013-04-11 |
20130090285 | METHODS OF TREATMENT WITH GLP-1 RECEPTOR AGONISTS - The invention provides methods for treating diabetes or obesity, as well as methods for inducing weight loss, preventing weight gain, or controlling weight in a patient in need thereof. The methods comprise administering to the patient at least one effective dose of a GLP-1 receptor agonist, or a regimen of GLP-1 receptor agonist comprising a plurality of substantially evenly spaced doses. The effective dose or regimen does not induce substantial nausea or appetite suppression in the patient. | 2013-04-11 |
20130090286 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS - Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming intramolecular bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, acylation, alkylation, substitution of carboxy terminal amino acids, C-terminal truncation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR). | 2013-04-11 |
20130090287 | Devices, Formulations, and Methods for Delivery of Multiple Beneficial Agents - The present invention relates to osmotic delivery devices, formulations, and methods for delivery of two or more beneficial agents. In one aspect, the present invention provides osmotic delivery devices useful for substantially concurrent administration of two or more beneficial agents. In another aspect, the present invention provides beneficial agent formulations for use in the osmotic delivery devices. The formulations include formulations wherein beneficial agents are soluble in the vehicle, suspension formulations comprising particle formulations of one or more beneficial agent, and combinations thereof. Further, methods for treatment of a variety of diseases or conditions using two or more beneficial agents are disclosed, wherein the methods are preferably practiced using the osmotic delivery devices and/or formulations of the invention. | 2013-04-11 |
20130090288 | Pharmaceutical compositions containing at least one protein active ingredient protected from digestive enzymes - The present invention relates to pharmaceutical compositions containing at least one protein active ingredient protected from digestive enzymes. Said pharmaceutical compositions contain said at least one protein active ingredient, in free form, as well as, for liquids, a system that buffers them to a pH greater than 4 and less than or equal to 8 or, for solids, a system that exerts, when they are placed a liquid medium, a buffer effect between a pH greater than 4 and a pH less than or equal to 8. | 2013-04-11 |
20130090289 | Method of Treatment of Type 2 Diabetes - Provided is a method of treating type 2 diabetes in a subject, comprising administering a polypeptide comprising thymosin, or an active fragment or variant thereof, preferably comprising or consisting of the peptide LKKTETQ (SEQ ID NO: 1). | 2013-04-11 |
20130090290 | BMP-2 Peptides and Methods of Use - The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors. | 2013-04-11 |
20130090291 | HEMOSTATIC COMPOSITIONS - The invention discloses a hemostatic composition comprising:
| 2013-04-11 |
20130090292 | TREATMENT OF DEGENERATIVE JOINT DISEASE - The invention provides a method of treating a degenerative joint disease. The method comprises administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP). The invention also provides a pharmaceutical product as well as a kit comprising DA-DKP. | 2013-04-11 |
20130090293 | PROTEIN SCAFFOLDS FOR TARGETED DELIVERY OF TOXIC IRON TO CANCER CELLS - Described herein are modifications and adaptations of iron storage proteins for a novel photo-initiated approach to cancer therapy whereby cells are killed via production of iron-generated hydroxyl radicals. The iron is photo-released from a protein scaffold that includes tumor-targeting peptides and/or proteins fused to the exterior surface of the protein scaffold. One or more photosensitizers are coupled to the protein shell. The multiple tumor-targeting peptides and/or proteins will bind to specific hyperexpressed receptors on the cancer cells. After binding of the photosensitizer-iron-loaded protein to the cancer cells, photochemical excitation of the photosensitizers with tissue-penetrating near-infrared light triggers release of “free” ferrous iron, which in oxic or mildly hypoxic intracellular environments generates toxic hydroxyl radicals via Fenton chemistry. This light-triggered release of “free” iron overwhelms the cancer cells' defenses against free radicals. The combination of tumor-targeting peptides and photo-triggered release of iron ensures that non-cancerous cells are not bombarded with iron. | 2013-04-11 |
20130090294 | NOVEL METHODS OF USE OF HSP70 FOR INCREASED PERFORMANCE OR TREATMENT OF HSP70 RELATED DISORDERS - The present invention relates to novel therapies that utilize exogenous HSP70 for the treatment of disorders or conditions regulated by HSP70 through administration of exogenous HSP70. | 2013-04-11 |
20130090295 | METHODS OF ACCELERATING MUSCLE GROWTH, DECREASING FAT DEPOSITS AND IMPROVING FEED EFFICIENCY IN LIVESTOCK ANIMALS - A method of promoting or improving the feed efficiency and the muscle to fat ratio in animals by administering to the animals a therapeutically effective amount of a pure or substantially pure RR-isomer of ractopamine is disclosed. Also disclosed are animal feed preparations and compositions and pharmaceutical preparations capable of increasing lean meat deposition in an animal or decreasing body fat, or promoting or improving the growth of an animal or improving the feed efficiency of an animal. Feed preparation, compositions and pharmaceutical preparations including therapeutically effective amounts of a pure or substantially pure RR-isomer of ractopamine are disclosed. | 2013-04-11 |
20130090296 | INJECTABLE FORMULATION OF A MACROCYCLIC LACTONE AND LEVAMISOLE - The present invention relates to formulations for controlling parasites, comprising a combination of macrocyclic lactone compound and levamisole wherein the levamisole is in particulate form suspended in a non-aqueous solvent | 2013-04-11 |
20130090297 | NUTRITIONAL COMPOSITIONS - Compositions for the promotion of muscle protein synthesis and control of tumor-induced weight loss in patients that are, for example, suffering from cancer cachexia, and methods of administering such compositions. | 2013-04-11 |
20130090298 | Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same - The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. | 2013-04-11 |
20130090299 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS - The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2013-04-11 |
20130090300 | INHIBITORS OF INFLUENZA ENDONUCLEASE ACTIVITY AND TOOLS FOR THEIR DISCOVERY - The invention provides inhibitors of influenza endonuclease activity and tools for their discovery. | 2013-04-11 |
20130090301 | AGENT FOR SUPPRESSING THE FORMATION OF ABNORMAL SKIN CELLS CAUSED BY EXPOSURE TO LIGHT - An object of the present invention is to provide an agent for suppressing the formation of skin cells induced by exposure to light such as ultraviolet light. The object is achieved by using a purine nucleic acid for suppressing the formation of abnormal skin cells caused by exposure to light. | 2013-04-11 |
20130090302 | ANTIVIRAL COMPOUNDS - The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2013-04-11 |
20130090303 | Agonists of PY2Y Receptor as a Treatment for Aortic Stenosis and Cardiovascular Calcification - The present invention relates to the treatment and/or prevention of aortic valve stenosis (AVS) and valve mineralization. Particularly, the invention provides a target for intervention in the treatment or prevention of AVS through the administration of the P2Y | 2013-04-11 |
20130090304 | COMPOSITIONS INCLUDING TRICIRIBINE AND TAXANES AND METHODS OF USE THEREOF - This application relates to combination therapies including triciribine and related compounds and taxanes and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation. | 2013-04-11 |
20130090305 | METHOD USING A DIETARY SUPPLEMENT FOR HEALING OR REGRESSING SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE, GASTRITIS AND ULCERS - The current invention presents a dietary supplement obtained from a mixture of melatonin, vitamins and aminoacids and administered for healing or regressing the symptoms of gastroesophageal reflux disease, such as heartburn, regurgitation, dysphagia, coughing, hoarseness, chest pain and odynophagia, gastritis and several types of ulcerations. | 2013-04-11 |
20130090306 | CHITOSAN BEADS AND FILLER COMPRISING SUCH BEADS - The present invention pertains to chitosan beads consisting of chitosan cross-linked with citrate ions. The present invention furthermore pertains to a filler comprising such chitosan-citrate beads. In one embodiment of the instant invention the filler is a dermal filler. In one further embodiment of the present invention the dermal filler is for the treatment of wrinkles and/or folds. In another embodiment of the instant invention the filler is for use in the treatment of a medical condition. The filler provided in the present invention may further comprise one or more active pharmaceutical ingredients. Further, the present invention pertains to a process for preparing the filler as claimed herein. | 2013-04-11 |
20130090307 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS - The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorder, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on Baclofen and Acamprosate combination. | 2013-04-11 |
20130090308 | COMPOSITIONS FOR THE TREATMENT OF DRY EYE - The present invention relates to ophthalmic compositions and methods useful to treat dry eye, or to diagnose, cure, mitigate, treat, or prevent dry eye syndrome in man or other animals. | 2013-04-11 |
20130090309 | AMINO-PYRIDINE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS - The invention provides certain amino-pyridine-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R | 2013-04-11 |
20130090310 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY - Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds. | 2013-04-11 |
20130090311 | BISPHOSPHONAMIDATE PRODRUGS AND USES THEREOF - Bisphosphonamidate prodrugs of therapeutic bisphosphonate compounds and uses thereof to treat diseases are described. | 2013-04-11 |
20130090312 | METHODS OF USE RELATED TO XEROSTOMIA - The present invention relates to new uses of thermally stable, crystalline S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by radiation treatment. In particular, the invention provides a method for treating or preventing xerostomia associated with the administration of radiation treatment of head and neck cancer. | 2013-04-11 |
20130090313 | pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME - Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts. Unexpectedly, carriers including free fatty acids (FFA) are able to deliver biologically active agents to various pH environments. Such targeted delivery is tailorable and useful for active agents that are: (a) injurious to the upper GI tract (esophagus, stomach, and duodenum), (b) acid labile, (c) impermeable/insoluble compounds in GI fluids, (d) susceptible to first pass metabolism, and/or (e) cause stomach irritation, upset, or dyspepsia. | 2013-04-11 |
20130090314 | SOLID STATE FORMS OF TAPENTADOL SALTS - Provided herein are novel solid state forms of tapentadol salts, process for their preparation, pharmaceutical compositions, and method of treating thereof. The tapentadol salts include an L-(−)-camphorsulfonate salt, a dibenzoyl-(L)-tartrate salt, a dibenzoyl-(D)-tartrate salt, a malate salt, a maleate salt, or a salicylate salt. | 2013-04-11 |
20130090315 | PROPHYLACTIC AND POST-ACUTE USE OF PROGESTERONE TO BETTER OUTCOMES ASSOCIATED WITH CONCUSSION - Compositions and methods for treating traumatic brain injury (TBI) and mild traumatic brain injury (mTBI) using progesterone and ent-progesterone are described. | 2013-04-11 |
20130090316 | Nasal Delivery Mechanism for Prophylactic and Post-Acute Use of Progesterone and/or itsEnantiomer for Use in Treatment of Mild Traumatic Brain Injuries - Compositions and methods for treating traumatic brain injury (TBI) and mild traumatic brain injury (mTBI) using progesterone and ent-progesterone are described. | 2013-04-11 |
20130090317 | PROPHYLACTIC AND POST-ACUTE USE OF PROGESTERONE IN CONJUNCTION WITH ITS ENANTIOMER FOR USE IN TREATMENT OF TRAUMATIC BRAIN INJURIES - Compositions and methods for treating traumatic brain injury (TBI) and mild traumatic brain injury (mTBI) using progesterone and ent-progesterone are described. | 2013-04-11 |
20130090318 | ONCE-A-MONTH METHOD OF CONTRACEPTION - The invention provides a method for providing contraception in a woman, wherein the woman is administered with a progestogen-only contraception composition once-a-month between the 1 | 2013-04-11 |
20130090319 | METALLOINSERTOR COMPLEXES TARGETED TO DNA MISMATCHES - A composition including a Rh or Ru metalloinsertor complex specifically targets mismatch repair (MMR)-deficient cells. Selective cytotoxicity is induced in MMR-deficient cells upon uptake of the inventive metalloinsertor complexes. | 2013-04-11 |
20130090320 | METHOD OF TREATING PROSTATE CANCER - A therapeutic method for treating prostate cancer is disclosed comprising administering to a patient in need of treatment a ruthenium complex salt. | 2013-04-11 |
20130090321 | METHOD FOR TREATING BRAIN CANCER - Methods and compositions for treating brain cancer are disclose including refractory brain cancer. | 2013-04-11 |
20130090322 | METHOD OF TREATING PANCREATIC CANCER - A therapeutic method for treating pancreatic cancer is disclosed comprising administering to a patient in need of treatment a gallium complex according to Formula (I) provided herein. | 2013-04-11 |
20130090323 | HETEROCYCLIC COMPOUNDS AND THEIR USES - Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer. | 2013-04-11 |